Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of funding to overhaul manufacturing on both sides of the Atlantic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,